DeepMed Research

Adebrelimab

Generic Name: Adebrelimab

Drug Type: Biotech

CAS Number: 2247114-85-6

Unique Ingredient Identifier: 1XBY50W1OX

Background: Adebrelimab is under investigation in clinical trial NCT03711305 (Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-stage (ES) Small Cell Lung Cancer (SCLC)).

Indication: 用于与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。

Clinical Trials

Adebrelimab Combined with Chemotherapy and Thoracic Radiotherapy for First-line Treatment of ES-SCLC

Phase 3

Not yet recruiting

Conditions: Extensive Stage Lung Small Cell Carcinoma

Interventions: Drug: Adebrelimab
Radiation: Radiation Therapy

First Posted Date: 2024-11-04

Last Posted Date: 2024-11-05

Lead Sponsor: Jinming Yu

Target Recruit Count: 524

Registration Number: NCT06672133

Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study

Phase 2

Recruiting

Conditions: Esophageal Cancer

Interventions: Drug: Adebrelimab combined with albumin-bound paclitaxel and cisplatin 4 cycle
Drug: Adebrelimab combined with albumin-bound paclitaxel and cisplatin 2 cycle

First Posted Date: 2024-10-29

Last Posted Date: 2024-10-29

Lead Sponsor: Tang-Du Hospital

Target Recruit Count: 80

Registration Number: NCT06663059

Locations: 🇨🇳
Tangdu Hospital Affiliated to the Fourth Military Medical University, Xi'an, Shannxi, China

Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC

Phase 2

Not yet recruiting

Conditions: Intrahepatic Cholangiocarcinoma (Icc)

Interventions: Drug: Adebrelimab
Drug: Irinotecan liposomes
Drug: 5-Fluorouracil (5-FU)
Drug: Lenvatinib
Drug: Calcium Folinate

First Posted Date: 2024-10-18

Last Posted Date: 2024-10-18

Lead Sponsor: Harbin Medical University

Target Recruit Count: 68

Registration Number: NCT06648525

Locations: 🇨🇳
Harbin Medical University, Harbin, Heilongjiang, China

A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma

Phase 1

Recruiting

Conditions: Advanced Urothelial Carcinoma

Interventions: Drug: SHR-A2102
Drug: Adebrelimab injection
Drug: SHR-8068 injection

First Posted Date: 2024-10-15

Last Posted Date: 2024-11-18

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 90

Registration Number: NCT06639347

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma

Phase 3

Recruiting

Conditions: Advanced Hepatocellular Carcinoma

Interventions: Drug: SHR-8068
Drug: Adebrelimab
Drug: Sintilimab
Drug: Bevacizumab

First Posted Date: 2024-10-01

Last Posted Date: 2025-05-15

Lead Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Target Recruit Count: 590

Registration Number: NCT06618664

Locations: 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China

A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer

Phase 2

Not yet recruiting

Conditions: Extensive-Stage Small Cell Lung Cancer

Interventions: Drug: Adebrelimab +Etoposide+Platinum-based drugs

First Posted Date: 2024-09-26

Last Posted Date: 2024-09-26

Lead Sponsor: Not specified

Target Recruit Count: 43

Registration Number: NCT06614621

Evaluating the Efficacy and Safety of Adebrelimab in Combination with Chemotherapy and LDRT As 1L Treatment for ES-SCLC

Phase 3

Not yet recruiting

Conditions: Small Cell Lung Cancer Extensive Stage

Interventions: Drug: Adebrelimab
Drug: Chemotherapy
Radiation: low dose radiotherapy

First Posted Date: 2024-09-24

Last Posted Date: 2024-09-24

Lead Sponsor: Sichuan University

Target Recruit Count: 202

Registration Number: NCT06610734

Phase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE

Phase 2

Recruiting

Conditions: Cholangiocarcinoma Cancer
Adebrelimab (SHR-1316)

Interventions: Drug: Adebrelimab and capecitabine
Drug: capecitabine

First Posted Date: 2024-09-23

Last Posted Date: 2025-01-16

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 122

Registration Number: NCT06607276

Locations: 🇨🇳
Jinling Hospital, Nanjing, Jiangsu, China
🇨🇳
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
🇨🇳
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China

and more 1 locations

Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer

Phase 2

Not yet recruiting

Conditions: Resectable Esophageal Squamous Cell Carcinoma

Interventions: Drug: Adebrelimab injection
Drug: Albumin-Bound Paclitaxel
Drug: Carboplatin injection

First Posted Date: 2024-09-19

Last Posted Date: 2024-09-19

Lead Sponsor: Shanghai Zhongshan Hospital

Target Recruit Count: 42

Registration Number: NCT06599775

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors

Phase 1

Not yet recruiting

Conditions: Non-Small Cell Lung Cancer
Advanced Solid Tumors

Interventions: Drug: HS-10370
Drug: Adebrelimab
Drug: Cisplatin
Drug: Pemetrexed
Drug: Carboplatin

First Posted Date: 2024-09-13

Last Posted Date: 2024-09-13

Lead Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Target Recruit Count: 350

Registration Number: NCT06594874

Locations: 🇨🇳
Union Hospital Tong Ji Medical College, HuaZhong University of Science and Technology, Wuhan, Hubei, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy